Table of Contents
1 Introduction
1.1 Definition
1.2 Scope of Study
1.3 Research Objective
1.4 Assumptions & Limitations
1.5 Market Structure:
2 Research Methodology
2.1 Research Process
2.2 Primary Research
2.3 Secondary Research
3 Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
3.5 Macroeconomic Indicators
4 Market Factor Analysis
4.1 Porter’s five forces model
4.1.1 Bargaining Power of suppliers
4.1.2 Bargaining Power of Customer
4.1.3 Intensity of Competitor’s
4.1.4 Threat of New Entrants
5 Middle East and Africa Anti-fungal Agents Market, by Therapeutic Indication
5.1 Introduction
5.1.1 Aspergillosis
5.1.2 Dermatophytosis
5.1.3 Candidiasis
5.1.4 Others
6 Middle East and Africa Anti-fungal Agents Market, by Drug Class
6.1 Introduction
6.1.1 Azoles
6.1.2 Pyrimidines
6.1.3 Echinocandins
6.1.4 Polyenes
6.1.5 Allylamines
6.1.6 Others
7 Middle East and Africa Anti-fungal Agents Market, by Route of Administration
7.1 Introduction
7.1.1 Oral
7.1.3 Local
7.1.4 Others
8 Middle East and Africa Anti-fungal Agents Market, by Country
8.1 Introduction
8.2 UAE
8.3 Egypt
8.4 Saudi Arabia
8.5 Kuwait
8.6 Qatar
8.7 Oman
9 Company Landscape
9.1 Introduction
9.1.1 Mergers Acquisitions
9.1.2 Collaborations
9.1.3 Release/New Product Launches
9.1.4 Other (Expansion, Updates, Partnership)
10 Company Profile
10.1 Novartis AG
10.1.1 Company Overview
10.1.2 Product/Business Segment Overview
10.1.3 Financials
10.1.4 Key Developments
10.1.5 SWOT Analysis
10.2 Pfizer, Inc.
10.2.1 Overview
10.2.2 Product/Business Segment Overview
10.2.3 Financials
10.2.4 Key Developments
10.2.5 SWOT Analysis
10.3 Sanofi-Aventis
10.3.1 Overview
10.3.2 Product/Business Segment Overview
10.3.3 Financials
10.3.4 Key Developments
10.3.5 SWOT Analysis
10.4 Merck & Co.
10.4.1 Overview
10.4.2 Product/Business Segment Overview
10.4.3 Financials
10.4.4 Key Developments
10.4.5 SWOT Analysis
10.5 Enzon Pharmaceuticals
10.5.1 Overview
10.5.2 Product/Business Segment Overview
10.5.3 Financials
10.5.4 Key Developments
10.5.5 SWOT Analysis
10.6 Bayer AG
10.6.1 Overview
10.6.2 Product/Business Segment Overview
10.6.3 Financials
10.6.4 Key Developments
10.6.5 SWOT Analysis
10.7 Astellas Pharma
10.7.1 Overview
10.7.2 Product/Business Segment Overview
10.7.3 Financials
10.7.4 Key Developments
10.7.5 SWOT Analysis
10.7 GlaxoSmithKline plc
10.7.1 Overview
10.7.2 Product/Business Segment Overview
10.7.3 Financials
10.7.4 Key Developments
10.7.5 SWOT Analysis
10.7 Abbott
10.7.1 Overview
10.7.2 Product/Business Segment Overview
10.7.3 Financials
10.7.4 Key Developments
10.7.5 SWOT Analysis
10.7 Sigma-Aldrich
10.7.1 Overview
10.7.2 Product/Business Segment Overview
10.7.3 Financials
10.7.4 Key Developments
10.7.5 SWOT Analysis
10.8 Others
11 Appendix
List of Tables
TABLE 1 MIDDLE EAST AND AFRICA ANTI-FUNGAL AGENTS MARKET, 2023-2030 (USD MILLION)
TABLE 2 MIDDLE EAST AND AFRICA ANTI-FUNGAL AGENTS MARKET, BY THERAPEUTIC INDICATION,2023-2030 (USD MILLION)
TABLE 3 MIDDLE EAST AND AFRICA ANTI-FUNGAL AGENTS MARKET, BY DRUG CLASS, 2023-2030 (USD MILLION)
TABLE 4 MIDDLE EAST AND AFRICA ANTI-FUNGAL AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
TABLE 5 MIDDLE EAST AND AFRICA ANTI-FUNGAL AGENTS MARKET, BY REGION, 2023-2030 (USD MILLION)
List of Figures
FIGURE 1 RESEARCH PROCESS
FIGURE 2 PORTERS FIVE FORCES MODEL
FIGURE 3 MIDDLE EAST AND AFRICA ANTI-FUNGAL AGENTS MARKET, BY THERAPEUTIC INDICATION
FIGURE 4 MIDDLE EAST AND AFRICA ANTI-FUNGAL AGENTS MARKET, BY DRUG CLASS
FIGURE 5 MIDDLE EAST AND AFRICA ANTI-FUNGAL AGENTS MARKET, BY ROUTE OF ADMINISTRATION
FIGURE 6 MIDDLE EAST AND AFRICA ANTI-FUNGAL AGENTS MARKET, BY REGION
FIGURE 7 MIDDLE EAST AND AFRICA ANTI-FUNGAL AGENTS MARKET: COMPANY SHARE ANALYSIS, 2020 (%)